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1. Introduction 
Tissue engineering and regenerative medicine (TE/RM) represents a broad spectrum of cell 
and biomaterial based approaches aiming to repair, augment and regenerate diseased 
tissues and organs. The successful recent clinical implantation of tissue engineered trachea, 
bladder and bladder derivative (Neo-Urinary ConduitTM) has highlighted the emergence of 
common methodological frameworks for the development of TE/RM approaches that may 
be broadly applicable towards the regeneration of multiple, disparate tubular organs.  
Similarly, recent progress towards regeneration of heart, kidney, liver, pancreas, spleen and 
central nervous system is identifying shared methodologies that may underlie the 
development of foundational platform technologies broadly applicable towards the 
regeneration of multiple solid organ systems. Central themes emerging for both tubular and 
solid neo-organs include the application of a biodegradable scaffold to provide structural 
support for developing neo-organs and the role of committed or progenitor cell populations 
in establishing the regenerative micro-environment of key secreted growth factors and 
extra-cellular matrix critical for catalyzing de novo organogenesis.  
However, aspects of these strategies currently under active development for tissue 
engineering of tubular and solid neo-organs may not be relevant for successful 
commercialization of neo-organs as novel TE/RM products for clinical application. For 
example, difficulties in large scale sourcing and quality control of biomaterials derived from 
decellularization of cadaveric organs imply that such biomaterials may be less suitable for 
incorporation into TE/RM products when compared to biomaterials of synthetic origin. 
Similarly, TE/RM technologies that attempt to leverage populations of stem and progenitor 
cells are less likely than platforms focused on committed cell populations or acellular 
biomaterials to facilitate rapid development of viable products.  
In this chapter, we will present our experience in the development of the Neo-Bladder 
AugmentTM, Neo-Urinary ConduitTM and Neo-Kidney AugmentTM to identify elements of 
this foundational organ regeneration technology platform that may be broadly applicable 
towards the design and development of additional tubular neo-organ products, including the 
esophagus and small intestine, the lung, the vasculature and the male or female genito-
urinary tract as well as additional solid neo-organs. We will focus specifically on 
highlighting aspects of these neo-organ regenerative platforms conducive to the commercial 
viability of such technologies.  
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2. Tissue engineering of tubular organs 
Two significant recent studies have brought the concept of de novo regeneration of tubular 
organs within humans towards proof-of-practice in the clinic. In the first example, seeding 
of tubular, biodegradable scaffolds with autologous urothelial and smooth muscle cells was 
shown to catalyze regeneration of a complete bladder with laminarly organized histology 
and associated urologic functionality upon implantation within seven pediatric patients 
(Atala et al., 2006). In the second example, a tissue engineered, functional human trachea 
was created using a decellularized, cadaveric tracheal segment as scaffold and seeded with 
autologous respiratory epithelial cells and chondrocytes generated by the directed 
differentiation of the patient’s own bone marrow cells (Asnaghi et al., 2009; Macchiarini et 
al., 2008).  
Both studies leveraged a scaffold seeded with autologous cells to trigger a regenerative 
response within the patient, ultimately leading to complementation of organ functionality 
with concomitant histogenesis of laminarly organized tissue structures. These approaches 
have focused on the regeneration of tubular organs and, taken together with additional 
recent developments in the regeneration of additional hollow organs, provide perspective 
into overlapping technology platforms and insight into key methodological differences that 
may impact the commercial feasibility of tubular organ engineering. In the following section 
(based on Basu & Ludlow, 2010), we discuss recent developments in tissue engineering of 
tubular organs.  
2.1 A Platform technology for tubular organ regeneration 
Organ regeneration technologies aim to restore the original structure and functionality of a 
diseased organ. Typically, healing responses within mammals are characterized by fibrosis 
and scar tissue formation, not regeneration. Tubular organ regeneration involves a specific, 
temporal sequence of cellular infiltration, vasculogenesis, neurogenesis and the defined 
differentiation of mucosal, stromal and parenchymal laminar tissue architectures (reviewed 
by Basu & Ludlow, 2010). Strategies for organ and tissue regeneration must therefore 
achieve the dual objectives of triggering a true regenerative response while ameliorating any 
tendency towards fibrotic repair. The methodology first pioneered for regeneration of the 
bladder (illustrated in Figure 1) may serve as a foundational platform for the regeneration of 
any tubular organ.  
 
 
Fig. 1. Tengion Neo-Bladder AugmentTM (NBA). Dome shaped biodegradable bladder 
scaffold (left panel) is placed in a support prior to seeding with cells and incubated in a 
bioreactor. The bioreactor is transported to the clinical site and the supported seeded 
scaffold removed (middle panel) and positioned for patient implantation (right panel).  
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Examination of the temporal sequence of neo-bladder regeneration in dogs illustrates the 
dichotomy in outcomes between implantation of acellular and cellularized scaffolds. This 
distinction is a principal theme of most studies describing the regeneration of tubular 
organs. Cell seeded scaffolds mediated a regenerative response within one month post-
implantation, characterized by induction of heavily vascularized, smooth muscle-like 
parenchyma. In contrast, acellular scaffolds triggered a principally fibrotic, reparative 
outcome characterized by randomly organized collagen fibers with minimal 
vascularization. 
Baseline urodynamics were reconstituted within four months of implantation with cell 
seeded scaffold, whereas the urodynamic profile of animals implanted with acellular 
scaffold remained abnormal throughout the trial period (Jayo et al., 2008a).  
In a related dog study, restoration of tri-laminar bladder wall architecture occurred within 
three months post-implantation and normal compliance characteristics of a urinary bladder 
wall developed by 12 months. Regenerated bladders were functionally and structurally 
stable for up to two years post-implantation. Importantly, although the construct volume 
was constant at implantation within variably sized dogs, the ratio of the regenerated 
bladder’s volume to host body weight adapted to the recipient animal’s size, demonstrating 
that the neo-organ responds to homeostatic mechanisms regulating organ volume (Jayo et 
al., 2008b).  
Although these canine studies utilized both bladder-derived urothelial and smooth muscle 
cells, urothelial cells have been shown to not be essential for bladder regeneration, thereby 
greatly facilitating process development and commercialization (Jack et al., 2009). However, 
use of bladder-derived smooth muscle cells is problematic in patients presenting with 
bladder related malignancies. Therefore, a number of alternate sources of smooth muscle 
cells have been investigated. Such alternate cell sources may have broad application in the 
regeneration of additional, laminarly organized tubular organs.  
One possible alternate source of smooth muscle cells may be the directed differentiation of 
mesenchymal stem cells (MSC) with recombinant, inductive cytokines such as transforming 
growth factor  (TGF-). Such MSC may be procured from bone marrow or adipose (Tian et 
al, 2010a,b; Sakuma et al., 2009). Additionally, autologous smooth muscle cells may be 
isolated from the vasculature of omentum or other adipose tissue as well as directly from 
the mononuclear fraction of peripheral blood (Basu et al., 2011a; Toyoda et al., 2009; Lin et 
al., 2008; Metharom et al., 2008).  
Although the use of MSC or other stem cell populations (adult-derived, embryonic or iPS 
(induced pluripotent stem cell)) for organ regeneration is informative as proof-of-concept, 
from a process development perspective focused on eventual manufacturing and product 
release, the requirements to monitor and control stem cell potential and directed 
differentiation towards a smooth muscle lineage substantially complicates efforts to 
streamline, standardize and assure quality, as well as leading to significant increases in cost 
of goods. To simplify bioprocessing procedures, enhance product consistency, reduce the 
risk of immune rejection and to ensure a robust supply of cellular raw material, we are 
focused on developing classes of committed smooth muscle cells for tubular organ 
regeneration (Basu et al., 2011a). 
An alternative platform technology for regeneration of bladder and related tubular organs 
including vas deferens and uterus is based around application of the peritoneal cavity as a 
living bioreactor to trigger the encapsulation of a tubular scaffold with myofibroblasts, as 
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demonstrated in rabbit and rat models (Campbell et al., 2008). Two to three weeks after 
implantation, tubular constructs were observed to be heavily encapsulated with 
myofibroblasts. These tissue engineered composites were anastamosed to the native organ 
and allowed to mature in vivo for up to 14 months. Histological analysis of regenerated 
tissue was performed together with evaluation of organ functionality. Bladder function was 
confirmed by normal urine flow, vas deferens function by ejaculation and uterine function 
by the ability to sustain pregnancy.  
With all three organ systems, an epithelial layer and laminarly organized musculature was 
observed with minimal evidence of inflammation. However, this approach may be 
impractical for widespread clinical application, as the cell encapsulation protocol represents 
an additional major surgical event. In vitro scaffold cell seeding is a simple and 
straightforward methodology sufficient to induce neo-organ regeneration in vivo. Use of 
alternate, non-bladder sources of smooth muscle-like cells will likely eliminate any 
requirement for peritoneal cavity based tissue engineering of bladder or bladder-like 
derivatives.  
2.2 Trachea 
Tissue engineered trachea illustrates another iteration of the foundational, bladder-based 
platform for tubular organ regeneration. Here, a decellularized, cadaveric tracheal 
segment was used as a scaffold. The recipient’s own epithelial cells seeded the luminal 
surface, while MSC derived from the recipient’s bone marrow was differentiated towards 
a chondrocytic lineage with recombinant cytokines prior to application on the abluminal 
surface. Although the patient showed reconstitution of pulmonary function within four 
months, detailed histological examination of the regenerated organ was not possible 
(Macchiarini et al., 2008).  
However, in a swine model of this tissue engineered trachea, both the chondrocytes derived 
from differentiated MSC as well as the epithelial cells were needed for host survival (Go et al., 
2010). While this methodology is valuable as proof of concept, it is clearly not amenable to 
large-scale process development. Decellularization of cadaveric scaffolds is an uncontrolled 
methodology that may not entirely alleviate immune response (Kasimir et al., 2006; Zhou et al., 
2010), as well as increasing cost of goods by the requirement to stringently monitor the 
decellularization protocol. Broader application requires synthetic biodegradable scaffold 
materials, facilitating reproducible manufacturability at large scale with defined chemical and 
physical properties. Furthermore, the application of directed differentiation strategies on cells 
destined for patient implantation may trigger additional regulatory hurdles, further 
complicating commercialization efforts. To this end, chondrocytes derived from autologous 
tracheal explants may be leveraged (Komura et al., 2008 a,b).  
2.3 Gastro-intestinal tract (GI) 
Individual components of the GI represent locally specialized iterative variations of 
essentially the same laminarly organized tubular histologic architecture as the bladder. 
However, from a commercial perspective, the small intestine represents by far the most 
pressing current clinical need, with small bowel transplantation being an unsatisfactory 
current standard of care for pediatric small bowel syndrome (SBS) 
(http://digestive.niddk.nih.gov/ddiseases/pubs/shortbowel/). Esophageal replacement 
for esophageal cancer may also be commercially viable.  
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The intestinal epithelium is the most highly regenerative tissue within adult mammals and 
may therefore be expected to be highly amenable towards tissue engineering or regenerative 
medicine methodologies. In one such study, in vivo derived organoid units, formed from 
incompletely disassembled clusters of epithelial and mesenchymal cells generated through 
partial digestion of intestinal epithelium (and therefore likely incorporating resident 
intestinal stem cells) were used to seed PLLA scaffold tubes that were subsequently 
matured within the peritoneal cavity of pigs. Seven weeks post-implantation, this tissue-
engineered small intestine recapitulated the gross overall laminar organization of native 
small intestine (SI) (Sala et al., 2009).  
Significantly, acellular scaffolds did not result in the regeneration of tissue engineered 
gastrointestinal structures. These data notwithstanding, anastamosis of these tissue 
engineered small intestines to host SI within a large animal model remains to be 
demonstrated. Additionally, up to 10cm of host SI was harvested to derive donor organoids 
that are not readily expandable in vitro. Whether organoid units capable of seeding a 
scaffold structure may be isolated from diseased human intestine, and how much diseased 
donor material may be needed, remain factors yet to be elucidated. The requirement to 
leverage the peritoneal cavity as a bioreactor for tissue engineering may also impede 
widespread application of this approach.  
The bladder-derived organ regeneration platform of biopolymeric scaffold seeded with 
smooth muscle cells may be applicable for regeneration of SI. To this end, stomach derived 
smooth muscle cells were used to seed a collagen-based scaffold prior to implantation 
within surgically isolated ileal loops of dogs for eight weeks, prior to re-anastamosis to the 
native intestine. Acellular collagen scaffold was used as a control. By 12 weeks post- 
surgery, macroscopic analysis of the cell seeded scaffold implantation site demonstrated 
regeneration of neo-mucosa resembling native mucosa. However, in animals containing an 
acellular scaffold, the implant site remained ulcerated up to 12 weeks post-implantation. 
Additional histological data showed significantly enhanced vascularization, 
epithelialization and organization of the circular muscle layer at the cell seeded scaffold 
defect site relative to acellular control (Nakase et al., 2006).  
Increasing the number of smooth muscle cells seeded onto the scaffold increased the area of 
regenerated SI tissue, although no concomitant increase in the thickness of the smooth 
muscle layer was observed (Nakase et al., 2007). Nevertheless, these data suggest that a 
simple regenerative platform composed of biodegradable scaffold nucleated with smooth 
muscle cells may be adequate to facilitate SI regeneration. Although this approach must be 
reproduced using a directly anastamosed tubular scaffold and alternate sources of smooth 
muscle cells, if successful, this methodology represents the most straightforward, clinically 
relevant and commercially viable strategy for regeneration of the SI.  
This organ regeneration platform technology may also be leveraged for regeneration of the 
esophagus. In one such example, patch defects were created in the abdominal esophagus of 
27 female rats, subsequently implanted with gastric acellular matrix (GAM). Of the 24 
survivors, none showed evidence of regeneration of the lamina muscularis mucosa even 18 
months post-implantation (Urita et al., 2007).  
In contrast, a study of a canine model of esophageal resection and replacement 
demonstrated that PGA tubes seeded with a mixture of keratinocytes and fibroblasts 
triggered regeneration of smooth muscle laminar organization similar to native esophagus 
within 3 weeks post-implantation, whereas acellular PGA tubes formed esophageal 
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strictures associated with near complete obstruction within two to three weeks (Nakase et 
al., 2008).  
In another dog study, cervical esophageal defects were patched with either small intestinal 
submucosa (SIS) alone, or SIS seeded with autologous oral mucosal epithelial cells. After four 
weeks, dogs implanted with cell seeded SIS showed almost complete re-epithelialization and 
minimal evidence of inflammation and, by eight weeks post surgery, regeneration of the 
underlying smooth muscle layer. Acellular SIS grafted animals presented only partial re-
epithelialization and a more extensive inflammatory response by four weeks, and no muscular 
regeneration by eight weeks post-implantation. Attempts to introduce an acellular SIS tubular 
construct into the cervical esophagus of piglets were also unsuccessful, demonstrating 
scarification and a minimal regenerative response (Doede et al., 2009). 
Progress has also been made in efforts to tissue engineer the stomach. Stomach derived 
organoid units, (analogous to the SI organoids used to tissue engineer the SI) upon seeding 
of a biopolymeric scaffold, triggered reconstitution of the gastric and muscularis mucosa in 
stomach tissue engineered within the peritoneal cavities of swine (Sala et al., 2009). In 
another study, circular defects were created in the stomach of seven dogs and a composite 
biodegradable scaffold (“New-sheet”), soaked with either autologous peripheral blood or 
bone marrow aspirate, was sutured over the defect. By 16 weeks post implantation, the 
defect site had formed regenerated stomach with evidence of re-epithelialization, formation 
of villi, vascularization and fibrosis within the submucosal layer. However, minimal 
regeneration of the smooth muscle layer was observed, as shown by expression of smooth 
muscle -actin, without expression of calponin, a marker of mature smooth muscle cells 
(Araki et al., 2009). 
Though strictly not a tubular organ, the anal sphincter is a component of the gastrointestinal 
tract and is critical in regulating patency of the large intestine. Recent efforts to engineer the 
anal sphincter leverage the same general platform used to catalyze bladder regeneration. To 
this end, smooth muscle cells isolated from human internal anal sphincter were seeded onto 
fibrin gels poured around a central mold. Cell mediated contraction of the gel around the 
mold resulted in the formation of a three-dimensional cylindrical tube of sphincteric smooth 
muscle tissue. Although in vivo anastamosis remains to be demonstrated, this bio-
engineered anal sphincter demonstrated contractile properties and response to defined 
neurotransmitters consistent with the functionality of native anal sphincter (Hashish et al., 
2010; Somara et al., 2009). Use of alternatively sourced smooth muscle cells may facilitate the 
transition of engineered sphincter towards commercial production.  
2.4 Neo-vessel 
Neo-blood vessels represent a major commercial opportunity for application of a tubular 
organ platform technology towards patients receiving bypass surgery. In a recently 
published clinical trial of vascular grafts composed of autologous bone marrow aspirate 
seeded onto a PGA/PCL scaffold and implanted into a cohort of 25 patients presenting with 
single ventricle physiology, all patients were asymptomatic 30 days post implantation and 
24/25 patients were alive at one year post-implantation (Hibino et al., 2010).  
Efforts to seed PGA tubular neo-vessel scaffolds with smooth muscle cells derived from the 
directed differentiation of bone marrow or adipose derived MSC with TGF- have also been 
described (Wang et al., 2010; Gong and Niklason, 2008). The requirement to induce directed 
differentiation with TGF- or related agents as well as the prolonged maturation period 
www.intechopen.com
 
Tissue Engineering of Tubular and Solid Organs: An Industry Perspective 
 
241 
under pulsatile conditions needed to achieve a mature smooth muscle phenotype will likely 
make this approach impractical for commercial application. A reliable source of committed 
smooth muscle cells (e.g., the vascular fraction of adipose or omentum) may represent a 
more commercially feasible platform. 
2.5 Lung 
Lung may be regarded as a highly specialized tubular organ amenable to regeneration with 
the bladder-based platform outlined above. Evidence to this effect was provided by a study 
examining the regenerative potential of PGA felt sheets seeded with adipose derived 
stromal cells in triggering pulmonary regeneration within a rat lung lobectomy model 
(Shigemura et al., 2006). The cell seeded PGA sheet was sealed onto the remaining lung lobe. 
Alveolar and vascular regeneration was observed within 1 week of implantation, with 
concomitant recovery of pulmonary functionality. Paracrine action by secreted factors 
including VEGF, HGF and FGF was suggested as a possible mechanism of action for 
triggering the regenerative effect.  
In another study, fetal rat lung cells were seeded onto gelfoam sponge-based scaffolds and 
implanted into adult rat lung. Alveolar-like structures with apparent vascular networks 
were observed to regenerate within degrading scaffold by 4 months post-implantation 
(Andrade et al., 2007). Importantly, the formation of these alvelolar like networks was 
observed to be strongly dependant on prior seeding of the scaffold with lung cells. As with 
the previous study, the authors suggest paracrine action of secreted factors from the seeded 
lung cells acting to facilitate regenerative in-growth of lung cells from the surrounding 
native lung tissue as the likely mechanism of action.  
Growth of lung cells in three-dimensions is essential to induce expression of epithelial genes 
related to lung morphogenesis, including FGFR2 (Mondrinos et al., 2006). Appropriate 
combinations of exogenous fibroblast growth factors chosen to target specific receptor 
isoforms may facilitate appropriate lung epithelial and mesenchymal cell behavior 
conducive to tissue regeneration (Mondrinos et al., 2007). Finally, tissue engineered lungs 
created from recellularized scaffolds derived from decellularized lung have also been 
recently characterized (Ott et al., 2010; Petersen et al., 2010; Cortiella et al., 2010). 
2.6 Genito-urinary system 
The recent reports of functional regenerated neo-phallus and neo-vagina within a rabbit 
model illustrate how foundational principles of tubular organ regeneration pioneered for 
bladder may be extrapolated to facilitate organogenesis of functionally distinct tubular 
organs (De Filippo et al., 2008). Decellularized corpora cavernosa was used as a collagen-
based scaffold matrix for seeding autologous corporal smooth muscle and endothelial cells 
in a rabbit model of penile replacement. Implantation of decellularized matrix alone led to 
formation of a non-functional, fibrotic phallus. However, cell seeded scaffolds regenerated 
corporal tissue organization histologically similar to native controls within 3-6 months post-
implantation. Tissue engineered phallus was functional as demonstrated by the ability of 
recipient animals to copulate normally (Chen et al., 2010).  
For the neo-vagina, autologous vaginal epithelial and smooth muscle cells were seeded onto 
the luminal and abluminal surfaces of PGA tubular scaffolds, preconfigured to resemble 
native rabbit vagina. Seeded composites were implanted in place of the native vagina of 
nine rabbits, with unseeded controls introduced into six other animals. As has been 
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observed for multiple organs, unseeded scaffold failed to trigger a regenerative response, 
whereas cell seeded scaffolds generated stage specific histogenesis, vascularization, 
innervation and regeneration of a patent neo-vagina by 6 months post-implantation with a 
defined muscular layer and a luminal invaginated epithelium. Organ functionality was 
confirmed by a graded contractile response of the musculature to electrical stimulation in a 
manner paralleling native tissue (De Filippo et al., 2008). 
2.7 Mechanism of action for tubular organ regeneration 
The lineage of cell populations constituting a regenerated neo-organ remains unclear. What 
is the contribution of the original cell population used to seed the scaffold compared to that 
derived from cellular migration from the surrounding tissue and/or omentum typically 
used to wrap neo-organs at the time of implantation as a source of neo-vascularization? 
Data addressing this issue was provided for the regenerated neo-vagina, where both the 
epithelial and smooth muscle cell populations used to seed the neo-vagina were labeled 
independently with fluorochromes and tracked to three months post-surgery. Labeled cells 
of both types were found to compose over 85% of the regenerated neo-organ (De Filippo et 
al., 2008).  
However, implantation of a human bone marrow derived cell seeded neo-vessel scaffold 
into immuno-deficient mice led to loss of all seeded human cells within days, followed by 
re-population of the scaffold with mouse monocytes and subsequent re-population with 
mouse smooth muscle cells and endothelial cells recruited via the monocyte chemoattractant 
protein MCP-1 (Roh et al, 2010). No direct contribution of the seeded bone marrow cells to 
the regenerated neo-vessel was observed. 
Organ specific mechanistic differences notwithstanding, these and results from other 
tubular organs demonstrate that defined populations of stem and progenitor cells are not 
required to trigger neo-organ formation. Smooth muscle cells and other committed cell 
types appear capable of mechanistically substituting for stem cells, by initiating cellular 
scaffold repopulation and catalyzing a host specific regenerative response that may 
additionally mediate paracrine signaling pathways to modulate recruitment of resident stem 
and progenitor populations, and regulate inflammation, immune response, apoptosis and 
fibrosis (Caplan, 2009). The ability to engineer neo-organs without a requirement for the 
isolation, expansion and manipulation of defined stem cell populations has greatly 
facilitated the commercial viability of this platform technology and will continue to do so in 
the future (Basu and Ludlow, 2010).  
2.8 Role of extracellular matrix (ECM) in regeneration 
An analysis of the bladder submucosal matrix generated by bladder smooth muscle cells 
identified multiple key paracrine signaling factors including VEGF, BMP4, PDGF-, KGF, 
TGF-1, IGF, bFGF, EGF and TGF- as resident components (Chun et al., 2007). This 
observation might suggest that the presence of living cells is entirely superfluous for 
triggering regeneration, which would greatly lower cost-of-goods for neo-organ production. 
A synthetic scaffold may be matured with an autologous, committed cell population to 
facilitate deposition of ECM, decellularized and implanted within the host to induce organ 
regeneration. Alternatively, defined ECM components or growth factors may be introduced 
into the scaffold to recapitulate key aspects of organogenesis (Sahoo et al, 2010). However, 
studies to date confirm that ECM alone in the context of, for example, an acellular matrix 
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such as small intestinal submucosa or bladder mucosa, is insufficient to induce 
organogenesis in vivo (Doede et al., 2009; Dorin et al., 2008). It is likely that living cells are 
required to modulate a more sustained, physiologically relevant regenerative response.  
2.9 Conclusions & clinical outlook 
We may summarize the key factors affecting the commercial viability of any tubular organ 
tissue engineering or regenerative technology platform as follows: 
 A biodegradable, synthetic scaffold based on well-characterized materials (e.g., PGA, 
PLGA) that is reproducibly manufactured with defined characteristics. 
 A population of committed cells (typically smooth muscle cells), easily isolatable and 
expandable, is required for scaffold seeding to trigger regeneration in vivo.  
 A purified population of defined stem cells is neither needed nor desirable. Cost of 
goods increases significantly with the requirements to monitor stem cell potential and 
to control directed differentiation. 
 Engineering an entire organ in vitro or within the peritoneal cavity is neither needed nor 
desirable. Instead, an in vitro cell seeded scaffold is adequate to trigger the body’s 
innate regenerative response, resulting in de novo organogenesis in vivo. 
The outlook for tubular organ regeneration in the clinic is promising. We have seen how the 
foundational technology platform consisting of a biodegradable scaffold nucleated with a 
population of committed smooth muscle cells, first pioneered for the bladder, may be 
applied towards regeneration of multiple, functionally disparate tubular organs. Proof of 
concept studies in human patients have already been successfully completed with neo-
bladder, trachea and vascular grafts. However, the neo-bladder continues to represent the 
pioneering regenerative neo-organ, with Phase 2 clinical trials currently underway 
[www.clinicaltrials.gov/ct2/show/NCT00512148?term=tengion&rank=4;  
www.clinicaltrials.gov/ct2/show/NCT00419120?term=tengion&rank=5]. Additionally, 
clinical trials are underway for the development of a neo-urinary conduit, a bladder 
derivative neo-organ designed to facilitate urinary diversion and developed through 
foundational principles closely resembling those used to engineer the neo-bladder 
replacement [www.clinicaltrials.gov/ct2/show/NCT01087697?term=Tengion&rank=3]. 
3. Tissue engineering of solid organs 
3.1 Introduction 
Though mammalian fetuses are capable of spontaneous regeneration of damaged organs 
and tissues until the third trimester, adult mammals typically respond to trauma by 
initiating reparative healing mechanisms. These are characterized by wound contraction, 
extensive fibrosis and scar tissue formation mediated by the migration and re-organization 
of myo-fibroblasts, as demonstrated during the response of the heart to ischaemic injury 
(Boudoulas and Hatzopoulos, 2009). True organ regeneration as commonly observed in 
certain species of fish and amphibian is associated with an absence of the fibrotic response 
and concomitant reconstitution of the three dimensional laminar or parenchymal 
organization of the regenerating organ, as exemplified by the regeneration of adult 
mammalian liver in response to lobectomy.  
The objective of de novo organ regeneration through tissue engineering or regenerative 
medicine is to use defined combinations of cells and biomaterials to catalyze a principally 
regenerative response towards organ trauma while simultaneously ameliorating any 
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tendency towards fibrotic repair. The de novo regeneration of a complete organ in mammals 
has been demonstrated for laminarly organized, tubular organs including bladder, trachea 
and vessels of the vasculature (Basu and Ludlow, 2010) as well as recently for the small 
intestine (Basu et al., 2011c). However, the regeneration of solid organs presents a unique 
challenge, requiring the organization of highly specialized cell types into complex three 
dimensional micro-architectures within a parenchymal matrix. Additionally, the 
regenerating solid neo-organ must synergize with developing elements of the vasculature, 
lymphatic and nervous systems throughout neo-organ morphogenesis.  
In this section, we will highlight the latest progress towards regeneration of solid organs in 
mammals, with an emphasis on identifying commonalities of methodology that may drive the 
creation of an organ regeneration platform broadly applicable towards multiple solid organ 
systems (Figure 2). We will focus on identifying aspects of the regenerative methodology most 
conducive towards translation into commercial process development and manufacture. 
 
 
Fig. 2. Solid organ systems potentially amenable to commercial tissue engineering strategies. 
From top, clockwise: central nervous system, heart, kidney, pancreas, liver. 
3.2 Kidney 
Kidney provides an excellent illustration of the considerable technical difficulties associated 
with solid organ regeneration. Numerous specialized cell types including podocytes, 
mesangial cells, endothelial cells, fibroblasts, epithelial cells and numerous stem and 
progenitor cell populations are organized across the renal parenchyma into discrete, 
specialized functional units or nephrons, which serve to selectively filter electrolytes from 
the vasculature (Vize et al., 2003; Basu et al., 2010).  
Efforts to trigger regeneration within animal models of ischaemic or chronic renal disease 
have typically centered around the isolation, expansion and re-introduction of defined 
populations of mesenchymal, embryonic or renal stem cells, potentially capable of site-
specific engraftment and directed differentiation along multiple renal lineages as well as 
facilitating the creation of a regenerative micro-environment through paracrine signaling 
mechanisms (reviewed by Sagrinati et al., 2008; Hopkins et al., 2009).  
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Such cell therapy methodologies have had generally mixed results, with little if any 
evidence supporting site specific engraftment and directed differentiation as a mechanism of 
action by exogenously applied stem or progenitor populations. Introduction of stem cells 
within the kidney by direct injection into the renal vasculature or renal parenchyma leads to 
apoptosis or efflux of the majority of applied cells from the target organ within days of 
implantation (Togel et al., 2008). Uncontrolled differentiation of stem cells that actually do 
engraft may also represent a significant technical challenge and potential regulatory obstacle 
against successful commercialization (Kunter et al., 2007).  
Reconstitution of kidney mass, a central prerequisite for true de novo organ regeneration, 
will likely require a cell/biomaterial scaffold composite facilitating the morphogenesis of 
glomeruli and tubules derived from seeded primary renal cell populations, as well as the 
migration and directed differentiation of host derived renal stem and progenitor cells within 
the scaffold framework, followed by progressive vascularization and innervation of the 
developing neo-organ, deposition of extracellular matrix and the reconstitution of a renal 
parenchyma. 
To this end, it may be reasoned that biomaterials derived from the native kidney are best 
suited to retain renal specific elements of the extracellular matrix (ECM) potentially capable 
of modulating renal morphogenesis as well as the three dimensional parenchymal micro-
architecture unique to the kidney. Application of sodium dodecyl-sulphate (SDS) detergent 
to whole rat kidneys in one recent report was shown to facilitate the removal of renal cells 
while maintaining the functional integrity of the ECM as well as the overall three 
dimensional parenchymal organization of the kidney. Murine pluripotent embryonic stem 
(ES) cells were applied to this renal scaffold via the renal artery or ureter, and the cell seeded 
biomaterial composite matured under static or pulsatile culture without the application of 
inductive differentiation agents.  
This approach permitted an evaluation of the specific effect of native renal-derived ECM in 
modulating the directed differentiation of the ES cell population. After arterial seeding, it 
was observed that ES cells localized within the Bowman’s capsule by 4 days post-seeding 
and within the associated vasculature and renal cortex by day 10. Niche specific localization 
of ES cells was accompanied by concomitant acquisition of the renal markers Pax-2 and Ksp-
cadherin as evidenced by histochemical and RT-PCR approaches (Ross et al., 2009). The 
effectiveness of SDS relative to other detergents in preserving components of the ECM as 
well as details of the renal micro-architecture was confirmed independently in comparative 
studies of the effect of decellularization within monkey kidneys with multiple detergent 
agents (Nakayama et al., 2010).  
Although it is not unreasonable to assume that the organ specific ECM and three 
dimensional histo-architecture associated with scaffolds procured by decellularization of 
native organs may be ideally suited to direct the potential regeneration of that specific organ 
type, this strategy may not be appropriate for a commercially viable solid organ 
regeneration platform. Apart from difficulties associated with the procurement of cadaveric 
organs for scaffold assembly, decellularization is a generally uncontrolled process not easily 
subject to scale-up, process development and quality assurance. Monitoring and verification 
of the extent of cell loss will substantially increase cost of goods associated with 
manufacture. Furthermore, native scaffolds retain the potential for immunogenicity despite 
the presumed absence of cells (Zhou et al. 2010). Reliable and reproducible 
manufacturability of solid neo-organs will likely require the application of synthetic 
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biomaterials with defined physical and chemical properties. With these considerations 
granted, progress towards creation of biosynthetic scaffolds appropriate for the regeneration 
of renal architecture was provided by the demonstration that tubular and glomerular 
structures spontaneously self-assembled from primary rat renal cell populations within one 
week of growth in collagen I gels (Joraku et al., 2009). 
The ability to introduce specific biomimetic peptides and defined proteolytic cleavage sites 
within the context of gel based biomaterials raises the intriguing possibility of controlling 
the morphogenesis of tubules, glomeruli or other renal structural units to modulate defined 
functional outcomes. For example, polyethylene glycol (PEG)-based hydrogels engineered 
with protease degradation sites and controlled densities of RGD peptide or laminin 
bioligands have been found to regulate epithelial morphogenesis of cysts derived from 
MDCK cells, such that cysts grown within ligand functionalized gels demonstrated an 
increased frequency of lumen formation and unambiguous baso-lateral polarization 
compared to those grown in unmodified hydrogels (Chung et al., 2008). Therefore, a true 
renal augment designed to trigger regeneration of glomeruli, tubules, EPO secreting 
fibroblasts (Paliege et al., 2010) or other key renal cell populations may potentially be 
envisioned as an injectable hydrogel containing functionalized matrix optimized to catalyze 
this defined regenerative outcome. Such methodologies alleviate potential concerns 
regarding the requirement for major surgical intervention within the diseased organ.  
Alternatively, a neo-kidney augment may be contemplated as a semi-permanent, 
implantable, cell/biomaterial composite that upon introduction within or adjacent to the 
renal parenchyma of a diseased organ, provides a foundational framework for regeneration 
of tubular or other renal superstructures as well as potentially establishing a regenerative 
microenvironment through paracrine mediated recruitment of native stem and progenitor 
populations as well as amelioration of inflammatory, fibrotic and apoptotic cascades 
(Caplan 2009). To this end, certain species of polyester fleeces have demonstrated the 
capacity to facilitate the growth of renal tubules within the context of a fibrous artificial 
interstitium.  
In this system, a heterogenous primary renal cell population incorporating stem and 
progenitor cells was extracted from the sub-capsular space of embryonic rabbit kidneys. The 
isolated cell population was sandwiched between two layers of polyester fleece and 
maintained within a perfusion culture system in the presence of aldosterone, a hormone 
involved in the renin/angiotensin axis (Vize et al., 2003). Spontaneous generation of tubular 
structures was observed with concomitant expression of key functional markers including 
cingulin and Na+/K+ ATPase. The regenerated tubules appeared to interact with the 
polyester fibers within the context of the artificial interstitium.  
The authors speculate that these cell seeded polyester scaffolds may be multiplexed by 
horizontal “tiling” or “paving” as well as vertical “piling” to create renal superstructures 
supporting the continued morphogenesis of renal tubules in vitro. The authors suggest that 
these compounded renal units could potentially form the basis of a true neo-kidney 
augment upon implantation within the sub-capsular space between the renal capsule and 
the renal parenchyma (Roessger et al., 2009; Minuth et al., 2008), although our observations 
of the mechanical properties of the renal capsule associated with diseased, fibrotic human 
kidneys suggest that this approach may not be feasible.  
Nevertheless, this methodology illustrates one key criterion for commercial viability; 
synthetic polyester fleeces are leveraged for regeneration of renal tubular superstructures, 
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without the requirement for extracellular matrix components derived from decellularized 
kidney or from other naturally occurring sources. In addition, the application of a defined, 
serum/BPE (Bovine Pituitary Extract) free media for tubule growth and maintenance 
additionally serves to facilitate large scale process development. Conversely, it remains to be 
ascertained whether cells derived from human kidney tissue in general and from diseased 
human organs in particular, are capable of supporting the spontaneous assembly of tubular 
structures de novo within the context of polyester or other synthetic polymer based 
biomaterial.  
At Tengion, development of the Neo-Kidney Augment (NKATM), a cell/biomaterial 
composite for renal tissue engineering, has focused on step-wise identification of bioactive 
cellular components and biomaterials amenable to implantation within renal parenchyma. 
To this end, we have leveraged principles discussed throughout this chapter, identifying 
lineage committed, primary renal cell populations as therapeutically bioactive agents 
capable of mediating functional rescue of aspects of disease phenotype within small animal 
clinical models of chronic kidney disease (Kelley et al., 2010; Presnell et al., 2010). Similarly, 
our evaluation of biomaterials compatible with renal parenchyma has led us towards 
application of gelatin hydrogels as the best tolerated biomaterial scaffold for renal tissue 
engineering (Basu et al., 2011b). Studies are currently underway to evaluate the ability of 
bioactive, primary renal cell/hydrogel biomaterial composite constructs (NKATM) to 
catalyze functional rescue of disease in small and large animal clinical models of chronic 
kidney disease. 
3.3 Heart 
Mammalian heart provides one of the clearest demonstrations of the inability of most 
mammalian solid organs to regenerate. Cardiac ischemia typically results in extensive 
fibrosis, scarification and loss of function (Boudoulas and Hatzopoulos, 2009). In contrast, 
zebrafish and other non-mammalian vertebrates are capable of complete regeneration and 
reconstitution of function upon removal of up to 20% of the ventricle, leading to speculation 
that an understanding of the mechanism of action underlying regeneration within model 
organisms such as zebrafish may identify analogous mechanisms that may be leveraged 
within mammals to trigger cardiac regeneration. To this end, dedifferentiation and 
proliferation of existing cardiomyocytes was shown to be the principal mechanism of 
regeneration following ventricular amputation within zebrafish (Jopling et al., 2010).  
This modality of action notwithstanding, tissue engineering approaches towards 
construction of functional mammalian heart have generally focused on decellularization of 
cadaveric organs to provide scaffold structures for reseeding and implantation. For 
example, neonatal rat cardiac or aortic endothelial cells were used to seed a decellularized 
cadaveric rat heart. Upon growth within customized bioreactors for 8 days, evidence of 
spontaneous contractility was observed. Pump functionality of up to 2% of adult was 
successfully reconstituted (Ott et al., 2008).  
However, although of interest as proof of concept, the requirement for cadaveric organs as a 
source of biomaterials may ultimately limit the usefulness of this methodology for 
commercial development and application within the clinic. As we have seen with the 
kidney, decellularization is a difficult procedure to monitor during quality assurance 
regimens, and there can be no guarantee that the resultant tissue engineered composite will 
lack immunogenicity upon implantation (Zhou et al. 2010). Furthermore, it remains to be 
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demonstrated whether cardiac cells derived from adult human tissue are capable of 
repopulating a scaffold to regenerate a functional organ. Finally, the requirement for tissue 
maturation within pulsatile bioreactors will likely substantially increase cost of goods for 
tissue engineered cardiac neo-organs.  
These criticisms aside, the engineering of synthetic scaffolds that recapitulate defined 
cardiac structures such as valves and chambers remains technically challenging (Fong et al., 
2008). We speculate that triggering the dedifferentiation and subsequent proliferation of 
existing cardiomyocyte populations by synthetic biomaterial composites containing defined 
biomimetic peptides and/or autologously derived lineage committed cell populations with 
smooth muscle cell-like properties may ultimately prove to be the more commercially 
feasible approach for regeneration of cardiac substructure and ultimately neo-organ 
regeneration.  
Evidence supporting the idea that biomaterial composites seeded with lineage committed 
cell populations may represent a potential solid organ regeneration platform comes from 
studies of biodegradable scaffolds nucleated with human ES cell derived cardiomyocytes 
alone or cardiomyocytes, endothelial cells and embryonic fibroblasts. Upon implantation 
within rat heart, more extensive vascularization was observed from tri-culture seeded 
constructs when compared to scaffolds seeded with ES cell derived cardiomyocytes alone 
(Lesman et al., 2010). In addition, acellular or mesenchymal stem cell (MSC) seeded SIS 
(small intestinal submuscosa) grafts have been implanted on the epicardial surface of a 
rabbit model of myocardial infarct. Resultant ventricular functionality and histopathology 
were significantly more improved in MSC seeded relative to acellular grafts.  
Finally, the use of injectable gels derived from decellularized human or porcine pericardium 
to trigger migration and proliferation of cardiomyocytes and cardiac progenitors has also 
been explored (Seif-Naraghi et al., 2010). Such synthetic hydrogels incorporating biomimetic 
peptides or containing committed smooth muscle, endothelial or other fully differentiated 
cell type may serve as a commercially feasible organ regeneration platform to trigger cardiac 
regeneration. These regenerative platforms most likely leverage paracrine and ECM-based 
signaling to recreate a regenerative micro-environment and thereby facilitate the 
regenerative response.  
3.4 Liver 
The regenerative potential of the liver is unparalleled among mammalian organs. Adult 
liver progenitors are thought to be defined by the population of “oval cells” capable of 
reconstituting both hepatocytes and biliary epithelium upon mobilization by an appropriate 
regenerative signal (Zaret & Grompe, 2008). However, as with the heart, liver regeneration 
does not appear to leverage discrete, organ specific pools of stem and progenitor cells, 
rather, operating through the increased proliferation of existing, mature hepatocytes. 
Unfortunately, this magnified proliferative capacity has not translated into the ready 
expandability of hepatocyte populations in vitro. Mammalian hepatocytes remain 
notoriously difficult to maintain and expand in culture (Underhill et al., 2007). Regardless, 
regenerative medicine and tissue engineering approaches to reconstitute the liver have 
typically focused on the isolation and expansion of mature, adult hepatocytes as a cell 
source for biomaterials seeding or, alternatively, on the directed differentiation of ES, iPS, 
adipose or bone marrow derived MSC towards a hepatic lineage followed by 3D culturing.  
Morphogenesis of the mammalian liver is triggered by induction of the embryonic 
endodermal epithelium by adjacent mesodermal populations (reviewed by Zaret & Grompe, 
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2008). Mimicking these early developmental signaling events through co-culture of 
hepatocytes with mesenchymal cell populations such as bone marrow-derived stem cells 
(BMSC) or even 3T3 fibroblasts results in significant enhancement of hepatic functionality as 
evidenced by prolonged maintenance of hepatocyte specific morphology and enhanced 
secretion of albumin (Nahmias et al., 2006). This observation raises the possibility that 
biomaterials seeded with mesenchymal cell populations may function as a potential solid 
organ regeneration platform, acting to facilitate the proliferation and functionality of 
hepatocytes in vivo.  
Evidence to this effect was provided by studies of Nagase analbuminea rats implanted with 
corraline hyaluronic acid (HA) ceramic disks seeded either with freshly isolated rat 
hepatocytes alone, or rat hepatocytes together with bone marrow derived mononuclear cells 
(Takeda et al., 2005). Hepatocytes cultured in the presence of BMSC secreted significantly 
more albumin into the media during in vitro culture relative to hepatocytes in monoculture. 
These effects were recapitulated in vivo within 4 weeks in analbuminic rats, within which 
HA-based biomaterials seeded with both BMSC and hepatocytes were associated with 
significantly greater blood serum albumin levels relative to monoculture controls. Finally, 
implantation of co-cultured biomaterials within mice presenting chemically induced liver 
damage resulted in complementation of blood serum albumin as well as increased levels of 
serum IL-6.  
This reconstitution of function notwithstanding, no evidence was provided regarding tissue 
regeneration in vivo within the context of the biomaterial, or whether the presence of 
hepatocytes is in fact essential. A clear demonstration of hepatic tissue regeneration and 
functional complementation using synthetic biomaterials seeded with BMSC or some other 
mesenchymal cell population would be of significant commercial interest. As with heart and 
kidney, we speculate that paracrine action by factors released from the seeded mesenchymal 
cells may be adequate to trigger angiogenesis and vascularization of the biomaterials as well 
as to stimulate the proliferation of the resident hepatocyte population. In keeping with the 
suggestion of paracrine mechanisms, it may additionally be possible to leverage the resident 
pluripotent progenitor populations normally resident in the liver by implantation of a 
biomaterial within the canals of Hering to provide additional space for the development of 
regenerated tissue (Zhang et al., 2008).  
Alternate cell sources of hepatocyte like cells may offer a potential substitute for mediating 
catalysis of liver regeneration. Hepatocyte like cells may be derived from bone marrow or 
adipose primary cells through a multi-step directed differentiation regimen attempting to 
phenocopy key signaling events during hepatic morphogenesis through the controlled 
application of recombinant bioactive factors and small molecules including hepatocyte 
growth factor (HGF), basic fibroblast growth factor (bFGF) and oncostatin-M (OMS) (Talens-
Visconti et al., 2006). These pseudo-hepatocytes display a characteristic polygonal 
morphology, demonstrate expression of key hepatocyte associated transcriptional and 
protein markers and secrete albumin into the media.  
Similarly, cells derived from the stromal vascular fraction of adipose can be driven to acquire 
hepatocyte-like characteristics by application of analogous multi-stage differentiation 
protocols. Importantly, both adipose derived hepatocytes as well as undifferentiated adipose 
stromal vascular fraction derived cells are capable of engraftment within chemically damaged 
liver in vivo, where they appear to form cords of tissue within the hepatic parenchyma and 
acquire hepatocyte specific functionality, as demonstrated by the in situ expression of albumin 
(Ruiz et al., 2010). In this study, engraftment by human adipose derived stromal cells within 
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the liver of a SCID mouse recipient was examined, with functionality being monitored through 
the use of antibodies specifically recognizing human albumin. The differentiation of bone 
marrow derived primary cells into hepatocyte-like cell types appears to be facilitated by 
growth in three dimensions, as shown by the enhanced secretion of albumin, urea, transferrin, 
serum glutamic pyruvic transaminase and serum oxaloacetate aminotransferase from 
hepatocyte-like cells grown in three-dimensions on polycaprolactate (PCL) scaffolds relative 
to similar populations maintained in two-dimensional monoculture (Ruiz et al., 2010).  
The trans-differentiation of bone marrow cells towards a hepatic phenotype may also be 
accomplished by leveraging paracrine and ECM mediated signaling mechanisms between 
existing hepatic cells and bone marrow cells. For example, human bone marrow MSC may 
be incubated in plates containing HepG2 derived ECM and HepG2 derived conditioned 
media for up to 30 days to facilitate the acquisition of a hepatocyte-like phenotype (Tai et al., 
2009). These hepatocyte like cells were seeded onto an RGD (arginine-glycine-aspartic acid) 
modified chitosan alginate polyelectrolyte fibrous non-woven scaffold prior to implantation 
within a rat liver lobectomy model presenting with 70% removal of liver mass. Post-
implantation analysis of the cell seeded biomaterials within 1-2 weeks confirmed the 
expression of key hepatic markers. Detection of human albumin within rat serum was also 
demonstrated. No histological evidence for regeneration was provided, although this 
outcome is unlikely over such a short time period. Taken together, these results provide 
evidence for functional complementation without clear demonstration of de novo hepatic 
tissue regeneration.  
An alternative, methodology for regeneration of hepatic tissue is based on the engineering 
of contiguous monolayers of primary hepatocytes through culturing on temperature 
responsive surfaces (Ohashi et al., 2007). The temperature sensitive polymer PIPAAm, upon 
decrease in temperature to below 32ºC, rapidly hydrates triggering the spontaneous 
detachment of cultured hepatocytes in the form of discrete, uniform sheets. Stacking of 
multiple hepatic tissue sheet monolayers within the subcutaneous space of mice resulted in 
the formation of a significant hepatic tissue mass, with histologically meaningful micro-
architecture, vascularization and functionality as assayed by the presence of glycogen. 
Importantly, ectopic engineered hepatic tissue was capable of reacting to a regenerative 
stimulus (2/3 liver resection) by significantly increased levels of proliferative activity. 
Furthermore, hepatocytes organized as stacked monolayer sheets generated significantly 
greater functional neo-organ volume compared to the same number of hepatocytes 
introduced into the subcutaneous cavity within an injectable Matrigel matrix. Such 
injectable hepatocyte matrices have been proposed as alternate regenerative stimuli for liver 
(Fiegel et al., 2009).  
3.5 Pancreas 
Strategies for regeneration of pancreas have focused almost exclusively on the de novo 
regeneration of pancreatic -cell populations. Morphogenesis of the pancreas broadly 
resembles hepatogenesis, with induction of the endodermal epithelium of embryonic foregut 
triggered by adjacent mesenchymal cell populations (Zaret & Grompe, 2008). As a result, 
methodologies developed to mediate the directed differentiation of ES or adult derived stem 
and progenitor cells towards a pancreatic lineage leverage many of the same key 
developmental morphogens as those formulated to mediate acquisition of hepatic phenotype.  
The forced expression of certain pancreatic transcription factors and/or treatment with 
defined growth factors is sufficient to trigger acquisition of insulin transcription within non-
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pancreatic cell populations as well as within pancreatic ductal and acinar cells, though 
typically not at levels comparable to true -cells. Lineage transdifferentiation and 
dedifferentiation towards a progenitor phenotype have been proposed as mechanisms of 
action underlying the observed de novo presentation of -cell specific phenotypes in vitro. 
Evidence is also accumulating that these mechanisms may operate in vivo to modulate true 
pancreatic regeneration (reviewed by Juhl et al., 2010).  
Strategies to specifically target pancreatic ductal and acinar cells for delivery of defined 
transcription factors selected to mediate dedifferentiation and reacquisition of a -cell specific 
phenotype, while useful as proof of concept, may not represent a commercially viable solid 
organ regeneration platform. Similarly, methodologies oriented around the directed 
differentiation of ES or adult stem cells will considerably increase cost of goods, with process 
development and quality assurance issues focused on the evaluation of stem cell potential and 
the extent and completeness of the directed differentiation process (see Table 1). To this end, it 
may be worthwhile exploring whether tissue engineering approaches for regeneration of 
pancreas may be designed to leverage the innate regenerative potential inherent within the 
organ itself. Although not as dramatic as the liver, regeneration of mammalian pancreas has 
been observed under certain circumstances (Cano et al., 2008).  
 
Stem Cells Committed Cells 
Considerable initial variability in 
proliferative capacity and multi-lineage 
differentiation potential 
Expansion in culture leads to loss of 
differentiation potential. Monitoring multi-
lineage differentiation potential is lengthy 
and expensive 
Directed differentiation is an uncontrolled, 
inefficient process. Only a proportion of cell 
population acquires lineage specific 
characteristics 
Requirement for inductive cytokines to 
direct lineage specific differentiation leads to 
significant increase in cost of goods 
Multiple molecular, proteomic and 
functional tests required to evaluate stem 
and differentiation potential. Substantial 
increasein time, cost, labor. Tests may be 
misleading and unreliable (Montzka et al., 
2009) 
Long term effects of inductive cytokines on 
cells implanted in vivo not known. Potential 
for transformation, teratoma formation 
Straightforward, readily isolatable cell 
sources, less subject to donor variability 
Readily expanded in culture without loss 
of lineage specific characteristics 
No requirement to monitor stem cell 
potential or directed differentiation 
No requirement for recombinant 
cytokines, substantially decreasing cost 
of goods 
No regulatory concerns regarding effects 
of recombinant cytokines on cell 
transformation 
Significant reduction in time required to 
expand committed cell population 
Application of committed smooth muscle 
cells (example) for organ regeneration 
demonstrated across multiple organ 
systems within in vivo models 
No possibility of abnormal in vivo 
differentiation or teratoma formation 
 
Table 1. Potential of Stem and Committed Cell Populations for Application in Commercially 
Viable Solid Organ Regeneration Platforms 
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Autologously derived pancreatic islet cells or alternate cell sources presenting a -cell like 
phenotype may be engineered within an appropriate gelatinous matrix or other biosynthetic 
scaffold. Considerable effort is currently being invested in developing pancreatic islet cell 
encapsulation technology, which may be manifested as a vascular device, microcapsule, 
tubular or planar membrane chamber or sheet architecture (reviewed by Sambanis, 2007). 
Encapsulation techniques facilitate the delivery of allogeneic or cadaveric islets cells by 
modulation of the host immune response. Recent developments in encapsulation 
methodologies include the application of bioactive hydrogels with functionalized moieties 
designed to improve -cell survival and secretion of insulin (Lin and Anseth 2009) as well as 
to modulate inflammation (Su et al., 2010). Implantation of PEG tubes containing rat islet 
cultures maintained on acellular pancreatic matrix was observed to lead to partial rescue of 
insulin secretory activity (De Carlo et al., 2010).  
Alternatively, pancreatic islet cells may be expanded through growth over polyglycolic acid 
(PGA) scaffolds. Scaffold seeded cells may then be further matured into tissue engineered 
islets within a thermo-responsive gel prior to harvesting and implantation beneath the 
kidney capsule of streptozotocin (STZ) induced diabetic mice, triggering a subsequent 
return to the normo-glycaemic condition (Kodama et al., 2009). Similarly, transplantation of 
pancreatic islets grown over a biodegradable scaffold composed of a vicryl fleece with 
polydioxanone backing and implanted within a canine total pancreatectomy model resulted 
in normo-glycaemia without the requirement for exogenous insulin injection (n=4), in one 
case up to 5 months post-implantation. In contrast, dogs receiving an equivalent mass of 
islets without scaffold did not become normo-glycaemic at any time (Kin et al., 2008).  
The sheet architecture solid organ regeneration platform pioneered for application in liver 
regeneration (Ohashi et al., 2007) has also been applied towards ectopic regeneration of 
pancreatic tissue (Shimizu et al., 2009). In this study, isolated rat pancreatic islets were 
expanded over laminin 5 coated PIPAAm plates. Implantation of the tissue engineered 
pancreatic sheets within the subcutaneous space of rats led to reconstitution of pancreatic-
like tissue structures within 7 days post-implantation. As with the liver, the authors 
speculate that stacking of pancreatic islet cell sheets may lead to regeneration of an 
increased mass of pancreatic tissue. It is noteworthy that none of these studies have 
examined the regeneration of native pancreas in situ. This may be a function of the 
additional challenges inherent in modulating regeneration in situ, including the requirement 
for vascularization and oxygenation specific to the internal volume of regenerating solid 
organs located deep within the peritoneal cavity. It will be of significant interest to evaluate 
whether islet cells implanted within biomaterials and ligated to lobectomized pancreas are 
capable of catalyzing partial de novo organ regeneration.  
3.6 Spleen 
Although the regeneration of spleen may not be clinically or commercially relevant, the 
principles developed for engineering these organs may have broader implications for solid 
organ regeneration. To this end, progress towards regeneration of spleen has been reported 
through the leveraging of platform technologies successfully applied towards engineering of 
small intestine and stomach, these representing examples of tubular, laminarly organized 
organs with fundamentally distinct micro- and macro-architecture compared to the spleen 
or other solid organs (Grikscheit et al., 2008).  
In this approach, organoid units generated by the incomplete digestion of rat splenic tissue 
were seeded within tubular PGA/PLA (poly-lactic acid) scaffolds, and the resultant 
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composites implanted within the omentum of the peritoneal cavity of splenectomized rats. 
This ectopic tissue engineered spleen demonstrated splenic tissue organization as well as 
providing protection against Pneumococcal induced septicemia. Interestingly, spleen slices 
cultured ectopically within omentum also mediated formation of quasi-spleen like 
structures capable of providing protection against induced septicemia. 
3.7 Central nervous system 
Potentially the best defined examples of a solid organ regeneration platform demonstrating 
evidence of cellular regeneration in situ within a damaged organ and catalyzed by 
implantation of a cell/biomaterial composite at the injury site comes from brain. Tissue 
engineering of brain and spinal cord typically involves the introduction of gel-based 
biomaterials within the brain that may be nucleated with neuronal stem cells and may 
additionally be supplemented with paracrine signaling factors such as vascular endothelial 
growth factor (VEGF), brain derived neurotrophic factor (BDNF) or components of the 
extracellular matrix including laminin and fibronectin.  
For example, a biomimetic hydrogel incorporating matrix metalloproteinase (MMP) 
degradation sites, a laminin derived peptide and the neurotrophic factor BDNF was shown 
to direct the in vitro differentiation of seeded mesenchymal stem cells towards a neuronal 
lineage. Subsequently, this biomimetic hydrogel was introduced into the intrathecal space 
within a rat model of spinal cord injury. Although no histological evidence for neuronal 
regeneration was presented, rats treated with the biomimetic hydrogel showed the greatest 
improvement in tests of locomotion compared to rats treated with non-biomimetic control 
hydrogels (Park et al., 2009). 
In another approach, defined brain defects were created within rat models and subsequently 
implanted with a gelatin based scaffold impregnated with VEGF. Histological evidence was 
provided as evidence for migration of endothelial, astroglial and microglial cells within the 
periphery of the scaffold at 30 days post-implantation (Zhang et al., 2008). This observed 
regenerative effect was found to be dependant on the presence of VEGF. A demonstration of 
the application of a non-gel based scaffold for tissue engineering of brain is the use of poly-
lactic-co-glycolic acid (PLGA) micro-particles in the 50-200 m size range. These neuro-
scaffolds were seeded with neural stem cells and introduced into the brain cavity of stroke 
induced rats by directed injection under magnetic resonance imaging (MRI) guidance. 
Within 7 days post-implantation, the neural stem cells had dispersed within the scaffold, 
and presented as a tightly packed mass at the center of the biomaterial, but with a broader 
distribution resembling a honey-comb like structure towards the periphery. The graft 
displayed a mixed population of neuronal, astrocytic and stem cell specific markers, 
together with evidence of inflammation, but little if any vascularization within the body of 
the biomaterial. No evidence was provided that the tissue engineered brain tissue had any 
functional significance in terms of impact to the rat stroke model (Bible et al., 2009). 
4. Conclusions 
When examined together, platform technologies for regeneration of solid organs remain 
largely as academic proof of concept. Factors needing to be addressed for successful 
commercialization include the following:  
 Synthetic biomaterials, readily manufactured with defined physical and chemical 
properties, approved by FDA for implantation within the human body. 
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 Avoidance of decellularized scaffolds that require cadaveric organ sources and may be 
potentially immunogenic. 
 Use of committed cell types, not stem or progenitor cell populations that require 
extensive monitoring of stem potential and directed differentiation. 
 Autologous cell sources where possible facilitate FDA acceptance of introduction of 
cellular material. 
 Emphasis on a platform approach: cell/biomaterial composites that upon delivery, 
trigger a broad regenerative response within multiple solid organs. 
This is in marked contrast to analogous platform systems developed for tubular organs such 
as bladder and bladder derivatives, which are currently undergoing Phase I/II clinical trials 
(Basu & Ludlow, 2010). As we have seen, there are few published reports documenting the 
in situ regeneration of a solid organ in response to damage as a function of the implantation 
of a cell/biomaterial composite. The majority of published reports have focused on tissue 
engineering approaches towards solid organ regeneration using the peritoneal cavity or the 
subcutaneous space as a living bioreactor to facilitate the vascularization of the regenerating 
composite that is a prerequisite for organogenesis. However, it is our position that such a 
methodology may not be conducive to large scale clinical application, nor does it represent a 
commercially viable developmental strategy.  
In this regard, a comparison with organ regeneration platforms developed for application 
towards the regeneration of laminarly organized tubular organs may be helpful. The use of 
committed smooth muscle cells seeded onto a biodegradable scaffold of synthetic polymer 
such as PGA, PLGA or PCL provides an example of a commercially viable organ 
regeneration platform that has been successfully applied towards regeneration of bladder 
and bladder derivatives. The serial stacking and piling of polyester fleeces nucleated with 
renal primary cell populations (Roessger et al., 2009; Minuth et al., 2008) may represent a 
viable solid organ regeneration platform amenable to process development, large scale 
manufacture and industrial quality assurance regimens, provided the caveats discussed 
earlier are addressed. Similarly, serial stacking of tissue sheets engineered by monolayer 
formation over temperature responsive PIPAAm surfaces as has been demonstrated for liver 
and pancreas may be viable for commercial development beyond proof of concept.  
Regenerative platforms that focus on committed cell populations such as hepatocytes, 
pancreatic islet cells and cells derived from the stromal vascular fraction of adipose instead 
of stem and progenitor cells have the potential to substantially reduce cost of goods by 
avoiding technical challenges associated with the isolation and expansion of stem cell 
populations, maintenance and monitoring of stem cell potential, monitoring and 
characterization of directed differentiation protocols and the costs associated with 
recombinant cytokines required to drive directed differentiation. Furthermore, introduction 
of mesenchymal stem cells within the renal parenchyma of rat models of glomerulonephritis 
has resulted in abnormal differentiation towards glomerular adipocytes, raising the 
potential for additional regulatory headaches. It remains unclear how the potential for mis-
directed differentiation within the solid organ parenchyma may be definitively eliminated 
(Kunter et al., 2007).  
The observation that adipose derived stromal vascular fraction cells are capable of 
engraftment in vivo within liver and present acquisition of hepatic functionality raises the 
possibility that readily isolatable adipose cells implanted within the context of synthetic 
biomaterials or as serially stacked tissue sheets may be capable of stimulating the innate 
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regenerative potential latent within liver, and potentially, additional solid organs. To this 
end, it has been reported that conditioned media from MSC enhance the survival and 
functionality of pancreatic islet cells following transplantation in diabetic rats (Park et al., 
2010).  
There is no evidence to indicate that the stem cell potential of these cell types is directly 
connected to their secretomic profiles: it is likely that fibroblasts or smooth muscle cells 
derived from these “MSC”-like populations may function just as effectively for paracrine 
signaling during the regenerative process. Such a combination of readily isolatable, 
committed cell types complexed with a biomaterial that may be reliably manufactured, has 
defined physical and chemical properties, and is already acceptable to FDA and other 
regulatory agencies for implantation within the human body would represent the ideal 
platform technology for the commercially viable regeneration of solid organs.  
To summarize, factors impacting successful commercialization of solid organ regenerative 
technologies include: 
 Identification of a synthetic scaffold structure that is broadly relevant to solid organ 
parenchyma, regardless of organ type. 
 Committed cell types that may be capable of triggering organ regeneration within the 
context of an implanted scaffold.  
 Alternatively, common approaches for the isolation of organ specific cell populations 
capable of mediating regeneration within the context of an implanted scaffold. For 
example, cell populations may be isolated from multiple solid organs by density 
centrifugation under standard conditions prior to scaffold seeding. 
 Standardized methodologies for combining organ derived or organ independent cell 
populations with biosynthetic scaffolds to create implantable composites, for example, 
stacking or piling of cell sheets. 
 A focus on methodologies that avoid prolonged maturation periods within bioreactors, 
but rely instead on triggering the body’s innate regenerative potential to stimulate neo-
organogenesis. 
 Identification of common mechanisms of action being leveraged across multiple organ 
types through common regeneration platforms. 
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